BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential
BioMarin Pharmaceutical (NASDAQ:BMRN) Adds US$792m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 28%
Earnings Preview: BMRN to Report Financial Results Post-market on May 01
BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying
Oppenheimer Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $98
Why BioMarin Pharmaceutical (BMRN) Is a Top Growth Stock for the Long-Term
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Sector Update: Health Care Stocks Decline in Afternoon Trading
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin
Unusual Options Activity: APA, DFS and Others Attract Market Bets, APA V/OI Ratio Reaches 3500.0
Truist Financial Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
Wedbush Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $94
William Blair Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating
BioMarin Pharmaceutical: Hold Rating Amid Promising Trial Results and Safety Concerns
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
BioMarin Pharmaceutical: Promising Growth Driven by Palynziq Success and Pipeline Opportunities
BioMarin Succeeds in Trial for Its Metabolic Disorder Treatment
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?